Effect of Weight Training on SDMT Scores in Patients With MS
Presenting at CMSC 2022, researchers investigated the effects of weight training on bone density, quality of life, and cognition in patients with MS.
CMSC 2022
Conference Coverage
Powered Exoskeleton Viable and Safe for Gait Training in Multiple Sclerosis
Presenting at CMSC 2022, researchers examined the use of powered exoskeletons for gait training, assessing practicality, safety, and clinical outcomes in patients with MS.
COVID-19 Infection, Vaccination May Unmask Underlying Neuroinflammatory Conditions
A case study presented at the 2022 CMSC Annual Meeting reviews a 47-year-old male patient who experienced relapsing steroid-responsive encephalomyelitis after SARS-CoV-2 infection and subsequent COVID-19 infection.
Ponesimod Use and Teratogenicity Risk in Women With Multiple Sclerosis
Presenting at CMSC 2022, researchers assessed the risk for reproductive and embryofetal toxicity in women exposed to ponesimod during pregnancy.
Diroximel Fumarate for Relapsing MS: How Does It Affect Clinical Outcomes?
Presenting at CMSC 2022, researchers assessed dimethyl fumarate outcomes among young adult patients with MS who participated in the open-label EVOLVE-MS-1 study.
Nabiximols Treatment Effect on Spasticity in Patients With MS
Presenting at CMSC 2022, researchers evaluated treatment outcomes among patients with MS spasticity being treated with nabiximols with or without such ASMs as baclofen.
Attack Severity in Neuromyelitis Optica Spectrum Disorder With Inebilizumab
Presenting at CMSC 2022, researchers evaluated the relationship between attack severity with serum (s) GFAP and sNfL, and the effect of inebilizumab on attack severity and serum biomarkers.
Health Care Utilization, Prodromal Symptoms Prior to Pediatric-Onset MS
Researchers sought to characterize health care utilization and identify and describe prodromal symptoms in patients with POMS.
Cognitive Processing Speed Changes in Relapsing MS With Ublituximab Treatment
Using the Symbol Digit Modalities Test, researchers evaluated changes in cognitive processing speed among patients with highly active RMS.
Therapy Selection, DMT Switching Patterns in Patients With MS
Presenting at CMSC 2022, researchers compared switch treatment patterns and therapy selection decisions between DMTs with anti-CD20 mechanism of action.
Fatigue in Early Multiple Sclerosis: Severity and Progression
Presenting at CMSC 2022, researchers described the progression of fatigue in patients with multiple sclerosis.
Safety, Efficacy of Dimethyl Fumarate for Multiple Sclerosis in Minority Groups
Presenting at CMSC 2022, researchers assessed the safety and efficacy of DMF for RRMS using real-world data.
Ofatumumab for Multiple Sclerosis Does Not Increase COVID-19 Severity
Presenting at CMSC 2022, researchers evaluated COVID-19 outcomes among patients with MS who received treatment with ofatumumab.
Risk for Multiple Sclerosis Relapse After Ponesimod Therapy Discontinuation
Researchers sought to determine whether patients who discontinued treatment with ponesimod had an increased risk for MS disease activity exacerbation.
Humoral Response to COVID-19 mRNA Vaccine in Patients With MS Receiving DMTs
Presenting at CMSC 2022, researchers evaluated the response to the mRNA-1273 vaccine in patients who received DMTs for MS.
Role of Race, Income in Optic Neuritis in Patients With NMOSD or MOGAD
Presenting at CMSC 2022, researchers evaluated whether racial patterns exist in NMOSD- and MOGAD-associated ON and the potential role of social disadvantage in these patterns.
Assessing Electrocardiography Alterations in Patients With Multiple Sclerosis
Presenting at CMSC 2022, researchers observed how ECG patterns relate to different demographic, clinical, and patient-specific characteristics in patients with MS.
Safety, Efficacy of Cladribine for Relapsing-Remitting MS: Real-World Data
Presenting at CMSC 2022, researchers obtained real-world data on the efficacy and safety of oral cladribine in patients with relapsing-remitting multiple sclerosis.
TMS for Multiple Sclerosis: Can It Help Treat Depressive Symptoms?
In a quantitative study, researchers assessed the efficacy of TMS on depressive symptoms in people with MS.
Neurofilament Light Chain Levels May Predict Multiple Sclerosis Disease Activity
Presenting at CMSC 2022, researchers evaluated the prognostic value of baseline NfL for predicting clinical relapse and change in MRI lesion activity among patients with MS.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in CMSC 2022
Loading... 
Loading...